• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.30% Nasdaq Up0.85%

    Pluristem Therapeutics, Inc. (PSTI)

    2.47 Up 0.01(0.40%) 2:27PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Pluristem Therapeutics, Inc.
    MATAM Advanced Technology Park
    Building No. 5
    Haifa, 31905
    Israel - Map
    Phone: 972 7 4710 8759
    Fax: 972 7 4710 8765
    Website: http://www.pluristem.com

    Index Membership:N/A
    Full Time Employees:160

    Business Summary 

    Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pluristem Therapeutics, Inc.

    Key Executives 
    Mr. Zami Aberman , 60
    Exec. Chairman and Chief Exec. Officer
    Mr. Yaky Yanay , 43
    Pres and Chief Operating Officer
    Mr. Boaz Gur-Lavie , 40
    Chief Financial Officer, VP of Fin. and Sec.
    Dr. William Prather RPh, M. D., 67
    Sr. VP of Corp. Devel.
    Ms. Efrat Livne Hadass ,
    VP of HR
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders